AR060813A1 - Moduladores de mglur5 iii - Google Patents

Moduladores de mglur5 iii

Info

Publication number
AR060813A1
AR060813A1 ARP070101786A ARP070101786A AR060813A1 AR 060813 A1 AR060813 A1 AR 060813A1 AR P070101786 A ARP070101786 A AR P070101786A AR P070101786 A ARP070101786 A AR P070101786A AR 060813 A1 AR060813 A1 AR 060813A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
fluoro
halogen
mglur5
Prior art date
Application number
ARP070101786A
Other languages
English (en)
Inventor
Methvin Isaac
Abdelmalik Slassi
Louise Edwards
Tao Xin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38565504&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR060813(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR060813A1 publication Critical patent/AR060813A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos novedosos, un proceso para su preparacion, trastornos del SNC y gastrointestinales, y composiciones farmacéuticas que los comprenden. Reivindicacion 1: Un compuesto de formula (1) en donde R1 es metilo, halogeno o ciano; R2 es hidrogeno o fluoro; R3 es hidrogeno, fluoro o C1-3 alquilo; R4 es C1-3 alquilo o ciclopropilo; X es (2) y Z es (3) en donde R5 es hidrogeno, C1-3 alquilo, C1-3 haloalquilo, C1-3 alcoxi; C1-3 haloalcoxi; o halogeno; R6 es hidrogeno, C1-3 alquilo, C1-3 haloalquilo, C1-3 alcoxi; C1-3 haloalcoxi; o halogeno; R7 es hidrogeno, fluoro o C1-3 alquilo; así como sus sales aceptables para uso farmacéutico, hidratos, isoformas, tautomeros y/o enantiomeros.
ARP070101786A 2006-05-05 2007-04-25 Moduladores de mglur5 iii AR060813A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79766506P 2006-05-05 2006-05-05

Publications (1)

Publication Number Publication Date
AR060813A1 true AR060813A1 (es) 2008-07-16

Family

ID=38565504

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101786A AR060813A1 (es) 2006-05-05 2007-04-25 Moduladores de mglur5 iii

Country Status (9)

Country Link
US (1) US20070259926A1 (es)
EP (1) EP2027110A2 (es)
JP (1) JP2009536211A (es)
CN (1) CN101437813A (es)
AR (1) AR060813A1 (es)
CL (1) CL2007001176A1 (es)
TW (1) TW200808777A (es)
UY (1) UY30306A1 (es)
WO (1) WO2007130822A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009054789A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,3-triazole pyrrolidine derivatives as modulators of mglur5
WO2009054786A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5
WO2009054790A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Amide linked heteroaromatic derivatives as modulators of mglur5
WO2009054785A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole ether derivatives as modulators of mglur5
EP2212316A4 (en) * 2007-10-26 2012-06-27 Astrazeneca Ab DERIVATIVES OF AMINO1,2,4-TRIAZOLES AS MODULATORS OF MGLUR5
TW200922586A (en) * 2007-10-26 2009-06-01 Astrazeneca Ab Thiophene 1,2,4-triazole derivatives as modulators of mGluR5
WO2009054787A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole carboxylic acid derivatives as modulators of mglur5
WO2009054791A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
WO2009054792A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Aminopyridine derivatives as modulators of mglur5
WO2012030887A1 (en) 2010-09-02 2012-03-08 Divergence, Inc. New compositions and methods for controlling nematode pests
WO2014152115A1 (en) 2013-03-15 2014-09-25 Monsanto Technology Llc N-,c-disubstituted azoles for controlling nematode pests
US20230028659A1 (en) * 2019-12-11 2023-01-26 Ambetex Pty Ltd Therapeutic compositions and methods for prevention and treatment of diastolic dysfunction

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003264018A1 (en) * 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
US20070185100A1 (en) * 2004-02-18 2007-08-09 Astrazeneca Ab Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
HUP0500921A2 (en) * 2005-10-05 2007-07-30 Richter Gedeon Nyrt Tetrazole derivatives, process for their preparation and their use

Also Published As

Publication number Publication date
WO2007130822A2 (en) 2007-11-15
EP2027110A2 (en) 2009-02-25
US20070259926A1 (en) 2007-11-08
UY30306A1 (es) 2007-11-30
CN101437813A (zh) 2009-05-20
CL2007001176A1 (es) 2008-01-04
WO2007130822A3 (en) 2008-01-03
JP2009536211A (ja) 2009-10-08
TW200808777A (en) 2008-02-16

Similar Documents

Publication Publication Date Title
AR060813A1 (es) Moduladores de mglur5 iii
AR060812A1 (es) Moduladores de receptores metabotropicos de glutamato mglur5, composiciones farmaceuticas que los contienen y usos en procesos patofisiologicos y trastornos que afectan el scn
AR060810A1 (es) Moduladores de receptores metabotropicos de glutamato mglur5, composiciones farmaceuticas que los contienen y usos en procesos patofisiologicos y trastornos que afectan el scn
CO6220935A2 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
CO6140060A2 (es) Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5
AR060652A1 (es) Moduladores de receptor glutamato metabotropico subtipo 5 (mglur5 ii)
AR050266A1 (es) Derivados de bencil-triazolona como inhibidores no nucleosidos de transcriptasa inversa
AR073136A1 (es) Compuestos de pirrol
CO6251247A2 (es) Imidazoquinolinas con propiedades inmuno-moduladoras
ES2564782T3 (es) Compuestos derivados de 1-aril-5-alquil pirazol, procedimientos de fabricación y procedimientos de utilización de los mismos
RS52261B (en) AMIDOPHENOX INDASOLS AS A USEFUL C-MET INHIBITOR
RS52900B (en) Benzoylpyrazole Compound, Process for Production and Production of Herbicides Containing Them
CY1110010T1 (el) Πυριδιναμινοσουλφονυλ υποκατεστημενα βενζαμιδια ως αναστολεις κυτοχρωματος ρ450 3α4 (cyp3a4)
UY31014A1 (es) Derivados de ftalazinona
CO5700763A2 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra
RS53133B (en) PIRAZOL DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS
CO6361956A2 (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmaceúticas que los contienen
AR058705A1 (es) Compuestos de bencimidazol como inhibidores del receptor vaniloide 1 (vr1)
AR070485A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
CR10671A (es) Compuestos azabiciclicos como inhibidores de la recaptacion de monoaminas
RS53909B1 (en) 5- (Phenyl / pyridinyl-ethynyl) -2-pyridine / 2-pyrimidine carboxamides as modulators of MGLUR5
HRP20110785T8 (en) Pyrimidinyl-piperazines useful as dopamine d3/d2 receptor ligands
AR073511A1 (es) Derivados de isoquinolinona como antagonistas de nk3
ECSP077167A (es) Nuevos compuestos heterociclicos
AR063374A1 (es) Derivados de benzoxazina y sus usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure